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ABSTRACT 
Objective: To investigate the immunogenicity, safety and toler- 
ability of three doses of a pentavalent vaccine produced by 
extemporaneous mixing of diphtheria-tetanus-whole cell per- 
tussis-hepatitis 6 virus (DTPw-HBV) and a lyophilized Haemo- 
philus influenzae type b (Hib)-tetanus conjugate vaccine in one 
syringe in comparison with separate, concomitant administra- 
tion of the same vaccine components in healthy infants at 1.5, 
3, and 5 months of age, following a dose of hepatitis B vac- 
cine at birth. 
Methods: An open, randomized, controlled trial was under- 
taken with 269 children allocated to two groups to receive three 
doses of Hib and DTPw-HBV vaccines as either a syringe mix 
or as separate injections in opposite arms. Symptoms were 
solicited on 4-day diary cards to assess reactogenicity and 
immunogenicity based on serum samples drawn immediately 
before the first dose and 1 month after the third dose. 
Results: There were fewer local and more general symptoms 
in the mixed vaccine group, but no statistically significant dif- 
ference in reactogenicity between the two groups. There were 
no withdrawals due to adverse experiences. Seropositivity rates 
were similar for all antigens in the two groups, with no clinically 
relevant differences in titers. 
Conclusions: The mixed DTPw-HBV-Hib vaccine was safe and 
well-tolerated, with high immunogenicity against all component 
antigens, and can be used to provide primary vaccinations of 
infants while increasing comfort. 
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The use of combination vaccines to immunize against 
several diseases simultaneously is a recognized strategy 
for increasing vaccine coverage in childhood vaccination 
programs. By reducing the number of injections, com- 
pliance to vaccination is improved and administrative and 
logistic costs incurred while implementing recommended 
vaccination programs are decreased. However, although 
combination vaccines offer protection for children against 
more infectious diseases with fewer injections, a poten- 
tial drawback is cross-interference between individual 
vaccine components when combined. 
The best characterized of such vaccines is the diph- 
theria-tetanus-whole-cell pertussis (DTPw) combination, 
which has been in widespread use since the 1940s. A 
further addition to this combination is one of the recently 
developed conjugate vaccines against Haemophilus 
injluenzae type b (Hib). Haemophilus injluenzae type 
b disease is associated with high rates of morbidity and 
mortality caused by Hib meningitis, epiglottitis, and pneu- 
monia. The development of Hib-conjugate vaccines has 
led to a dramatic decrease in the incidence of Hib disease 
in industrialized countries where Hib vaccination has 
been implemented. l 
The World Health Organization (WHO) has actively 
encouraged the implementation of Hib vaccination in 
developing countries. In a recent clinical trial inThe Gam- 
bia, which has a high incidence of invasive Hib disease 
in the very young, a DTPw-Hib mix vaccine had a 95% 
efficacy against all invasive Hib disease.z The inclusion of 
Hib vaccines in the DTPw combination is intended to 
increase compliance and hence decrease incidence of 
Hib disease. Currently, there are four commercially avail- 
able Hib vaccines that can be combined with DTPw as 
one injectable vaccine.3 
In addition to the injectable DTPw vaccines and the 
oral polio vaccines, the WHO Expanded Program of 
Immunization (EPI) recommends vaccination of all chil- 
dren against Hepatitis B virus (HBV) by 1997.4 As part of 
the EPI the WHO recommended the development of a 
combined DTPw-HBV vaccine. SmithKline Beecham Bio- 
logicals (Rixensart, Belgium) has developed such a vac- 
cine (TritanrixTM-HB) to fulfill this goal. The 
WHO-recommended schedule for such a vaccine is three 
doses at 6, 10, and 14 weeks of age, with the inclusion 
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of a hepatitis B vaccination at birth in areas of high 
endemicity where there is risk of perinatal transmission.5 
The aim of the present study was to investigate whether 
a pentavalent vaccine produced by the extemporaneous 
mixing of Tritanrix T”-HB and a commercial Hib (Hiber- 
ixTM) vaccine in one syringe would be immunogenic, 
safe, and well tolerated, in comparison with separate, 
concomitant administration of the same vaccines in 
opposite limbs. Such a combination of DTPw, Hib, and 
HBV vaccines would facilitate inclusion of the HBV vac- 
cine into current national immunization schedules. 
MATERIAL and METHODS 
The study was approved by the local and national ethics 
review committees in Myanmar, and conducted at the 
investigating physician’s center (Central Women’s Hos- 
pital,Yangon, Myanmar), according to the Declaration of 
Helsinki and Good Clinical Practice guidelines effective 
at study initiation. Written informed consent in the local 
language (Burmese) was obtained from the parents or 
guardians of all children entered into the trial. 
Trial Design, Vaccines, and Schedules 
The study design was open, randomized, and controlled 
with two groups of healthy neonates. Neonates with an 
Apgar score of 7 or higher 5 minutes after birth and 
who had no concomitant administration of immunoglob- 
ulins were enrolled and randomly assigned to one of two 
groups to receive one intramuscular dose of a commer- 
cial Hepatitis B vaccine (EngerixTM-B, SmithKline Beecham 
Biologicals) containing 10 Fg recombinant hepatitis B 
surface antigen (HBsAg), within 24 hours of birth. 
Between 5 and 8 weeks of age infants were eligible 
to continue in the study if they were not participating in 
other trials, had no acute disease, and were not receiving 
immunosuppressive therapy. Other exclusion criteria 
were a history of allergic disease; any symptom or sign 
of systemic dysfunction, especially of the central nervous 
system (CNS); and any previous vaccination with similar 
vaccines other than oral polio and BCG. 
At approximately 1.5, 3, and 5 months of age and 
according to the local schedule, eligible subjects assigned 
to group 1 received three doses of the mixed vaccine: a 
tetravalent DTPw-HBV vaccine containing 30 International 
Units (Iv) or more of adsorbed diphtheria toxoid, 60 IU 
or more tetanus toxoid, 4 IU or more of whole-cell per- 
tussis antigen, and 10 Fg recombinant HBsAg per 0.5 mL 
dose, which was used to resuspend one dose of the 
lyophilized Hib-tetanus conjugate vaccine (10 Fg polyri- 
bose-ribitol phosphate [PRP] conjugated to about 30 kg 
tetanus toxoid adsorbed to 0.63 mg alumina). Following 
the same schedule, subjects in group 2 were administered 
the same DTPw-HBV and Hib vaccines as separate injec- 
tions in opposite limbs; the Hib vaccine was reconstituted 
with 0.6 mL saline diluent in this case. All vaccines were 
manufactured by SmithKline Beecham Biologicals. 
Data Collection 
Demographic and reactogenicity data were collected from 
diary cards completed by parents or a study nurse on 
the day of vaccination and during the 3 days following 
each dose, and transferred to a Standard Case Report 
Form (CRF) by the investigator.The intensity of solicited 
local symptoms: pain on digital pressure and the size of 
redness and swelling at the injection site, and systemic 
symptoms: fever (axillary temperature measured with a 
supplied thermometer), irritability, drowsiness, unusual 
crying (persistent inconsolable screaming or crying for 
more than 3 hours within 48 hours of vaccination), feed- 
ing problems (not taking the bottle or breast-feeding as 
usual), diarrhea (loose stools), and vomiting, were 
recorded by parents. The parents or study nurse graded 
the symptoms as either absent, mild (easily tolerated), 
moderate (sufficiently discomforting to interfere with 
infant’s daily activity), or severe (prevents normal daily 
activity).The relation of the solicited and unsolicited 
symptoms to the vaccinations was assessed by the physi- 
cian at each subsequent visit of the vaccinee. Because 
the study was open to the investigator, diary cards and the 
subsequent transcription to the CRFs were checked by 
blinded clinical monitors from SmithKline Beecham to 
minimize possible discrepancies or bias. 
Subsequent doses were not to be administered if any 
adverse experiences occurred: i.e., fever (axillary tem- 
perature) 40°C or higher within 48 hours after the vac- 
cination, persistent crying for more than 3 hours within 
48 hours after vaccination, or any symptoms and signs 
indicative of CNS disorders or hypersensitivity reactions 
to the vaccine. Any serious adverse events, including life- 
threatening events, or any case of hospitalization were 
to be reported by the physician to the sponsor within 24 
hours of occurrence. 
Serology 
At birth set-a were prepared from maternal cord blood for 
screening for HBsAg, anti-HBs and anti-Hepatitis B core 
antigen (anti-HBc). Before the first dose of the DTPw- 
HBV and Hib vaccines and 1 month after administration 
of the last dose (month 6) venous blood samples were 
drawn, and sera were prepared and stored for subsequent 
serologic assays. 
All serologic testing was performed in a blinded fash- 
ion at SmithKline Beecham Biologicals. Antidiphtheria and 
antitetanus antibodies were determined by enzyme-linked 
immunosorbent assay (ELISA), with a cutoff of 0.1 IU/mL, 
above which there is a good correlation between the ELISA 
and in vivo neutralization tests.‘,’ Bordetella pertussis anti- 
bodies were determined using a whole-cell based com- 
mercial kit with an assay cutoff of 15 ELISA. U/mL 
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Table 1. Anti-HBs: Seropositivity and Geometric Mean Titers One Month after Administration of Combined Vaccines 
Postvaccination Seropositive* Postvaccination 
Subjects (%) GMT (m/U/ml) (95% C/) 
Status at Birth Month 1.5 Month 6 Month 6 
Group 1 (Mixed) (n = 127) n = 47 (37) n=127 (100) 1124 (884-1430) 
Seronegative (n = 63) n = 1 (1.6) n= 63 (100) 1426 (1030-l 974) 
Seropositive (n = 64) n = 46 (71.9) n= 64 (100) 890 (625-1267) 
Group 2 (Separate) (n = 122) n = 35 (28.7) n = 120 (98.4) 1272 (971-1668) 
Seronegative(n = 75) n = 1 (1.3) n = 74 (98.7) 1424 (1004-2020) 
Seropositive (n = 47) n = 34 (72.3) n = 46 (97.9) 1063 (685-1649) 
*Seroprotective titer 2 IO IU/mL. 
(Labsystem, ICNFLOW, Helsinki, Finland). Anti-HBs anti- 
body titers were measured using a commercial radioim- 
munoassay kit (AUSAB, Abbott Laboratories, North Chicago, 
IL) with a cutoff of 10 mIU/mL. A radiolabelled antigen 
binding assay @ABA) was used to measure the antibodies 
against the Rib polysaccharide, PRP, with a cutoff of 0.15 
kg/mL. All cutoff values were considered to be seropro- 
tective titers, with the exception of B.pertussis, for which 
there is no serologic correlate. 
Statistical Analyses 
The ratio of male to female subjects was compared 
between groups using the Fisher’s exact test, and mean 
ages were compared between groups and sexes using a 
two-way analysis of variance (ANOVA). A one-way ANOVA 
was used to compare postvaccination geometric mean 
titers (GMT) between groups. Fisher’s exact test was used 
to compare the percentages of vaccine recipients 
seropositive for diphtheria, tetanus, HBs, and PRP anti- 
bodies, and vaccine response rates against the pertussis 
component. A vaccine response was defined as the 
appearance of detectable antibodies in previously 
seronegative subjects and the maintenance of titers in 
previously seropositive subjects. This latter definition 
takes into account the expected decrease in maternal 
antibody titers in the period between pre- and postvac- 
cination blood samples; the half-life for decay of mater- 
nal pertussis antibodies is approximately 40 days8 
RESULTS 
Of 286 neonates screened and vaccinated with HBV vac- 
cine at birth, there were 17 subjects excluded because 
subsequent vaccines were not administered according to 
protocol.The remaining 269 children eligible for the reac- 
togenicity analysis were randomly assigned to group 1 
(137) and group 2 (132). Of these, 249 were eligible for 
the immunogenicity analysis, because 16 did not comply 
with the required vaccination schedule and four did not 
comply with the blood sampling schedule, leaving 127 
vaccine recipients in group 1 and 122 in group 2. All chil- 
dren who received the first dose of combined vaccine 
completed the full vaccination course. Both groups were 
statistically comparable according to gender and age. 
Immunogenicity 
The numbers of seropositive subjects and antibody GMTs 
postvaccination are shown in Table 1 for the hepatitis B 
vaccine components.There were no statistically significant 
differences in the prevaccination antibody status between 
the two groups. All vaccine recipients receiving the mixed 
vaccine (group 1) and 98.4% given separate vaccines 
(group 2) had anti-HBs titers indicative of seroprotection 
1 month postvaccination (see Table l).There was no sig- 
nificant difference between the GMTs of the two groups 
postvaccination. Although there was a tendency for the 
presence of maternal antibodies at birth to result in lower 
Table 2. Postvaccination Seropositivity and Geometric Mean Titers for Mixed and Separate Vaccine Administrations 
Group 1 Group 2 
Mixed DTPwHBV-Hib Separate DTPw-HBV + Hib 
N Seropositive Subjects (%) GMT N Seropositive Subjects (%) GMT* 
Vaccine Component [95% c/j [95% Cl] [95% C/l [95% C/l 
Diphtheria 126 113 (89.7) 0.652 120 117 (97.5) 0.880 
[82.7-94.21 [0.515-0.8261 [92.3-99.41 [0.733-1.0561 
Tetanus 127 127 (100) 2.618 122 121 (99.2) 1.174 
[96.3-1001 [2.213-3.1971 [94.9-1001 [0.962-1.4331 
Pertussis 126 126 (100) 140.7 122 122 (100) 148.4 
[96.3-1001 [128.8-153.71 [96.2-l 001 [134.2-164.11 
PRP (Hib) 127 125 (98.4) 6.103 122 119 (97.5) 5.722 
[93.9-99.71 [4.842-7.6931 [92.4-99.41 [4.240-7.7221 
*Geometric mean titers for diphtheria and tetanus in IU/mL, in ELISA U/mL for pertusis, and in pg/mL for PRP 
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Table 3. Incidence of Symptoms per Number of Doses of Vaccine with which Reaction Was Observed 
Local Symptoms 
Number of Reactions Reported 
All Symptoms (%) 
(Doses) 
DTPw-HBV-Hib 
(%) (Doses) 
DTPw-HBV 
(%) (Doses) 
Hib 
(%) (Doses) 
Systemic Symptoms 
(%) (Doses) 
Group 1 (Mixed) 
397 66.8 (265) 38.5 (153) - - 61.7 (245) 
Group 2 (Separate) 
385 62.9 (242) - 41.3 (159) 19.7 (76) 56.6 (218) 
postvaccination titers of anti-HBs antibodies, this did not symptoms were slightly, but not significantly, lower in the 
result in significant differences between the subjects who mixed vaccine group than observed for DTPw-HBV alone 
were initially seropositive or seronegative. (Table 4). 
The mixed vaccine group had a lower percentage of 
seropositive vaccine recipients (89.7% vs. 97.5%, P = 
0.018) and a lower GMT for antidiphtheria antibodies 
(0.652 and 0.88 IU/mL in the mixed and separate groups, 
respectively (p = 0.0499) (Table 2), but the clinical rele- 
vance of these differences is limited as all subjects had 
titers above the seroprotective level (0.01 IU/mL). Con- 
versely, the GMT for antitetanus antibodies was signifi- 
cantly higher in the mixed vaccine group (2.618 IU/mL) 
than the group given the vaccines separately (1.174 
IU/mL) (P < O.OOl), with no significant difference in the 
number of seropositive subjects for this antigen (100% 
and 99.2%, respectively). 
Systemic symptoms were reported in 61.7% and 
56.6% of children in groups 1 and 2, respectively (see 
Table 3), of which fever, irritability, and unusual crying 
were the most frequent (see Table 4). Of the 396 diary 
cards returned by the mixed vaccine group, 183 (46.1%) 
contained reports of systemic symptoms considered to be 
related to the vaccination. As shown in Table 4, there 
were no significant differences between the two groups 
with regard to the total incidence of general symptoms, 
or the number considered to be related to the vaccina- 
tion. 
One month after the third dose, all subjects were 
seropositive for pertussis with similar titers in groups 1 
and 2 of 140.7 and 148.4 EL.U/mL, respectively. Similarly, 
there was no difference in the response to the Hib com- 
ponent between the two groups, with 98.4% and 97.5% 
having titers 0.15 pg/mL or higher, and 91.3% and 86.9% 
1 .O kg/mL or higher in groups 1 and 2, respectively, with 
GMTs of 6.103 and 5.722 kg/mL, respectively. 
Reactogenicity 
There were no more reactions reported in the mixed vac- 
cine group (66.8% of doses) than in the separate group 
(62.9%). There were no significant differences in the over- 
all incidences of local or systemic symptoms between 
the two groups (Table 3). Incidences of individual local 
The most clinically relevant systemic symptom was 
considered to be fever.There were two reports of fever 
over 39°C in the mixed vaccine group, in vaccine recip- 
ients who developed intense swelling, redness, and pain 
at the injection site, which resolved in 7 to 10 days after 
treatment with antibiotics and antipyretics. Severe fever 
was associated with a similar injection site reaction at 
the DTPw-HBV site of one subject in the second group, 
the only serious adverse event reported, which devel- 
oped after the last dose and required hospitalization. Fol- 
lowing treatment with oral cloxacillin (250 mg/d), the 
child recovered within 4 days. Reports of severe irri- 
tability and unusual crying were 1% (mixed group, n = 
4) and 1.6% (separate, n = 6) and 0.8% (mixed, n = 3) and 
1.3% (separate, n = 5) respectively, 
The incidences of local reactions were similar at the 
sites of the DTPw-HBV-Hib and DTPw-HBV injections, 
Table 4. Incidence of the Most Frequent Systemic and Local Symptoms and of Those Assessed as Being Related to the Vaccination by 
the Investigator 
Symptom 
Mixed DTPW-HBV-Hib 
(n = 396)* 
Total (%) Related (%) Total (%) 
Separate DTPw-HBV+Hib 
(n = 385) 
Related (%) Total (%) 
Systemic 
Fever 
Irritability 
Unusual crying 
219 (55.3) 166 (41.9) 201 (52.2) 152 (39.5) - 
136 (34.3) 60 (15.2) 148 (38.4) 51 (13.2) 
48 (12.1) 22 (5.6) 65 (16.9) 25 (6.5) - 
Local 
Pain 
Redness 
Swelling 
127 (29.5) All 127 (33.0) All 65 (16.9) 
103 (26.0) All 110 (28.6) All 42 (10.9) 
105 (26.5) All 111 (28.8) All 40 (10.4) 
*One subject’s diary card was not returned. 
Mixed vs. separate: fever: P = 0.512; irritability: p = 0.474; unusual crying: P = 0.652 
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the separate Hib vaccine being associated, as expected, 
with fewer reactions (see Table 3). Severe pain was 
reported after five (1.3%) of the doses of mixed vaccine, 
six (1.6%) of the DTPw-HBV doses, and four (1%) of the 
Hib doses given as separate vaccines. There were no 
reports of severe redness or swelling. 
DISCUSSION 
The administration of DTPw-HBV and Hib vaccines as a 
mixture in a single injection produced a lower total inci- 
dence of injection site symptoms and, numerically slightly 
more general symptoms than separate administration of 
the two vaccines, although this was neither statistically 
nor clinically significant in either case.The incidence of 
local symptoms with the mixed vaccine was similar to 
that of the DTPw-HBV alone, showing that the extra Hib 
component did not increase the reactogenicity. Severe 
reactions, although infrequent, were also associated to 
the same extent with the mixed and separate adminis- 
trations.The only serious adverse event, an inflammatory 
reaction, occurred at the site of a separate DTPw-HBV 
injection, and was successfully resolved following treat- 
ment with antibiotics. Although the study was open for 
the assessment of reactogenicity, in view of the similar- 
ity of the reactogenicity profdes in the two groups the 
authors are confident that no bias was introduced. 
The DTPw-HBV mixed with Hib induced protective 
antibody titers against diphtheria, tetanus, hepatitis B, and 
H. influenzue and high antipertussis titers. Combinations 
of antigenic components from different organisms are 
known to cause variable effects on individual titers, 
decreasing one or other of the antibody titers.9-17 
Scheifele et al report that immunologic responses vary 
with the DPT preparation used to resuspend the PBP-T 
conjugated vaccine.9 The present study showed no sig- 
nificant decrease in any of the antibody titers after mix- 
ing, with the exception of diphtheria. Indeed, the mixed 
vaccine induced equal or higher antibody responses 
against the other four antigens when compared to sepa- 
rate administration. Although a decrease in the anti-PRP 
response has been described when some DTPw and Hib 
vaccines were mixed in the same syringe,’ mixing did 
not cause a reduction in titers of anti-PRP antibodies using 
the specific PRPT and DTPw-HBV vaccines in the present 
study. Despite the smaller GMTs in the mixed group, the 
antidiphtheria titers were well above the protective cut- 
off titers in both groups. Significantly higher antitetanus 
titers were elicted in the mixed vaccine group compared 
to the separate injections. 
The antibody titers elicited in this study are equiva- 
lent to those observed in other trials of the DTPw-HBV 
vaccine.18-2o The WHO recommend that 95% or more of 
infants receiving DTPw and HBV vaccinations should 
have protective antibody titers against HBV (10 mIU/mL) 
after a three-dose primary vaccination course.5 A further 
recommendation of the EPI is that three tetravalent vac- 
cine doses of DTPw-HBV should be used as the primary 
vaccination course in countries with low HB prevalence, 
whereas in regions with high perinatal transmission a 
HB, monovalent vaccine dose should be given at birth 
followed by three doses of DTPw-HBV as in this study.The 
mixed vaccine used in this trial fulfills the hepatitis B 
requirement in this situation. 
The mixed pentavalent vaccine is thus proven to be 
as immunogenic and safe and better tolerated than sep- 
arate, simultaneous injections due to the elimination of 
the extra injections for the separate Bib vaccine and, as 
could be shown, the attributable side-effectsThe use of 
such a vaccine will allow the integration of hepatitis B 
vaccines into national childhood immunization sched- 
ules, as recommended by the WHO Expanded Program 
of Immunization, without the need to introduce a new 
vaccination. This will ensure that compliance is main- 
tained, by improving patient comfort while also keeping 
to a minimum the increase in costs that a new vaccine 
entails in terms of administration, logistics, and storage. 
This study extends and confirms the results of recent 
reports describing the safety and immunogenicity of this 
combined DTPw-HBV vaccine. 18-2o The current study was 
intended to investigate the feasibility of using a DTPw- 
HBV-Hib combination vaccine as a primary course by 
extemporaneously mixing the DTPw-HBV and Hib vac- 
cines in one syringe before administration, with the inten- 
tion of developing such a formulation. These results 
support the possibility of syringe-mixing of currently mar- 
keted commercial vaccines as licensed in the European 
Union. This recommendation should not be generalized, 
however, as the data from this study apply only to the 
two specified vaccines, TritanrixTM and HiberixTM, and 
alternative vaccines should be investigated with regard to 
non-interference before use as syringe mixes. 
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